

FOI REF: 21/186

Eastbourne District General Hospital

Kings Drive  
Eastbourne  
East Sussex  
BN21 2UD

21<sup>st</sup> April 2021

Tel: 0300 131 4500

Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

**We are analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:**

• Abatacept [Orencia]	32
• Adalimumab [Humira]	35
• Adalimumab [Amgevita]	2
• Adalimumab [Hymiroz]	0
• Adalimumab [Imraldi]	263
• Adalimumab [Idacio]	0
• Apremilast [Otezla]	9
• Baricitinib [Olumiant]	92
• Certolizumab [Cimzia]	24
• Etanercept [Enbrel]	23
• Etanercept Biosimilars	259
• Filgotinib [Jyseleca]	0
• Golimumab [Simponi]	55
• Infliximab [Remicade]	2
• Infliximab Biosimilars	64
• Ixekizumab [Taltz]	2
• Rituximab [MabThera]	4
• Rituximab Biosimilars	34
• Sarilumab [Kevzara]	3
• Secukinumab [Cosentyx]	92
• Tocilizumab [Ro Actemra]	70
• Tofacitinib [Xeljanz]	13
• Upadacitinib [Rinvoq]	0
• Ustekinumab [Stelara]	5

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to Lynette Wells, Director of Corporate Affairs, East Sussex Healthcare NHS Trust ([lynette.wells2@nhs.net](mailto:lynette.wells2@nhs.net)) quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)  
Corporate Governance Manager  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)